Alzheimer’s Early Detection Act of 2026
Latest action (22 Jul 2026): Introduced
What this bill does
H.R. 9823, the Alzheimer's Early Detection Act of 2026, would require group health plans, individual and group health insurance issuers, and state Medicaid programs to cover Alzheimer's biomarker testing—including blood, tissue, or other biospecimen analyses used for early detection, diagnosis, risk assessment, treatment selection, or monitoring of Alzheimer's disease. Insurers could not impose cost-sharing, treatment limits, or step-therapy requirements stricter than those applied to other medical benefits, and any prior authorization request would need a decision within 72 hours (or 24 hours in urgent cases), with automatic approval if that deadline is missed. Coverage must also promote equitable access, including for rural and underserved populations.
The bill affects patients and families dealing with Alzheimer's disease, health care providers ordering biomarker tests, and insurers and state Medicaid agencies that must adjust coverage and administrative practices. The private-insurance provisions would take effect for plan years beginning one year after enactment, and the Medicaid provisions would apply to calendar quarters beginning one year after enactment. The bill also directs the National Institutes of Health, through a contract with the National Academies of Sciences, Engineering, and Medicine, to study and report to Congress annually for three years on the value of biomarker testing for Alzheimer's detection and treatment.
The bill was introduced on July 22, 2026, by Rep. Jake Auchincloss with Rep. Juan Ciscomani as a cosponsor, and referred to the House Committee on Energy and Commerce. It has not yet received a committee vote, floor action, or further congressional consideration.
Plain-English summary generated by Bill100 AI from the official record. Always verify against the source below.
Official summary
This bill is in the first stage of the legislative process. It was introduced into Congress on July 22, 2026. It will typically be considered by committee next before it is possibly sent on to the House or Senate as a whole.
Common questions
- What does H.R. 9823 do?
- H.R. 9823, the Alzheimer's Early Detection Act of 2026, would require group health plans, individual and group health insurance issuers, and state Medicaid programs to cover Alzheimer's biomarker testing—including blood, tissue, or other biospecimen analyses used for early detection, diagnosis, risk assessment, treatment selection, or monitoring of Alzheimer's disease. Insurers could not impose cost-sharing, treatment limits, or step-therapy requirements stricter than those applied to other medical benefits, and any prior authorization request would need a decision within 72 hours (or 24 hours in urgent cases), with automatic approval if that deadline is missed. Coverage must also promote equitable access, including for rural and underserved populations. The bill affects patients and families dealing with Alzheimer's disease, health care providers ordering biomarker tests, and insurers and state Medicaid agencies that must adjust coverage and administrative practices. The private-insurance provisions would take effect for plan years beginning one year after enactment, and the Medicaid provisions would apply to calendar quarters beginning one year after enactment. The bill also directs the National Institutes of Health, through a contract with the National Academies of Sciences, Engineering, and Medicine, to study and report to Congress annually for three years on the value of biomarker testing for Alzheimer's detection and treatment. The bill was introduced on July 22, 2026, by Rep. Jake Auchincloss with Rep. Juan Ciscomani as a cosponsor, and referred to the House Committee on Energy and Commerce. It has not yet received a committee vote, floor action, or further congressional consideration.
- Has H.R. 9823 become law?
- Not yet. As of 22 Jul 2026, H.R. 9823 is introduced.
- Who sponsored H.R. 9823?
- H.R. 9823 was sponsored by Rep. Jake Auchincloss [D-MA4] (Democrat-MA), with 2 cosponsors.
- What's the latest action on H.R. 9823?
- Introduced (22 Jul 2026).
Related bills in Health
Expressing support for the designation of September 22, 2026, as “National Hispanic Nurses Day” and recognizing the National Association of Hispanic Nurses as the leading organization representing and advocating for Hispanic nurses.
Recognizing the importance of protecting continuous Medicaid coverage for individuals undergoing active cancer treatment.
Wildland Firefighter Health and Safety Act
Expressing support for the designation of the third week of September as “Fungal Disease Awareness Week” and encouraging efforts to improve awareness, diagnosis, treatment, surveillance, and prevention of fungal diseases in the United States.
Bill100 mirrors the public U.S. legislative record from Congress.gov and GovTrack and adds plain-English AI summaries. It is an information tool, not legal, compliance or lobbying advice, and it is not affiliated with the U.S. Congress or any government agency. AI summaries can simplify or omit detail — every bill links to the official source; verify there before you rely on it.